Answers are grounded in this paper and cite their sources.
We appreciate your valuable comments on our paper “Trends in Usage and Drug Costs of Immune-Checkpoint Inhibitors in Japan [1].” We also thank you for providing this opportunity to address the points you raised. As you correctly noted, this paper does have limitations. Data on individual patient clinical outcomes, dosage, treatment duration, regimens, etc., cannot be obtained from the National Database (NDB) open data. Currently, several registries do exist in the cancer field, but they are not nationwide in scope and present constraints such as covering only limited cancer types, like rare cancers or cancers of unknown primary origin. Therefore, regardless of the data sources used, it is impossible to obtain detailed information on post-marketing usage patterns, which is one of the challenges in Japanese healthcare. Furthermore, unless post-marketing clinical trials (Phase IV) are conducted, information on efficacy cannot be obtained, making it impossible to reassess efficacy after market approval—another significant challenge.
No takes yet. Share an insight, caveat, or question.
Takami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: